Metraipolis › archive › dc_be579be05478

Reduced-Dose Pazopanib as First-Line Therapy in Metastatic Renal Cell Carcinoma: Real-World Outcomes and Subsequent Treatment Patterns from a… — Europe PMC PMID:42745780

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42745780
DOI
10.15586/jkc.v13i3.495
License (as archived)
solo-consultazione
Archived
2026-10-08T04:50:55.644Z
SHA-256 of the archived text
07ec755cfb79fca53dd6712dc10d24a75a4efa6ad59b787b6ee0ab70b86e7b39
Stable URL of this page
https://metraipolis.com/documento/dc_be579be05478

How to cite

Reduced-Dose Pazopanib as First-Line Therapy in Metastatic Renal Cell Carcinoma: Real-World Outcomes and Subsequent Treatment Patterns from a… — Europe PMC PMID:42745780 — Europe PMC (en), https://europepmc.org/article/MED/42745780 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_be579be05478 (Metraipolis archive dc_be579be05478, sha256 07ec755cfb79fca53dd6712dc10d24a75a4efa6ad59b787b6ee0ab70b86e7b39)
BibTeX
@misc{dcbe579be05478,
  title = {Reduced-Dose Pazopanib as First-Line Therapy in Metastatic Renal Cell Carcinoma: Real-World Outcomes and Subsequent Treatment Patterns from a… — Europe PMC PMID:42745780},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42745780},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_be579be05478; sha256 07ec755cfb79fca53dd6712dc10d24a75a4efa6ad59b787b6ee0ab70b86e7b39},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42745780. Agents can read the archived copy with the MCP tool read_document.